+++ 822.167 Pressemeldungen +++ 33.992 Newsrooms +++ 6.000 Medien +++

Nutra Pharma CEO, Rik J. Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company

(PresseBox) (Coral Springs, Fla., ) Nutra Pharma Corporation (OTCBB: NPHC.OB), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J. Deitsch , had published a Shareholder Letter on the Company's website.

"We have been very busy here at Nutra Pharma," explained Rik J. Deitsch , Chairman and CEO of Nutra Pharma Corporation. "I wanted to take this opportunity to outline the progress that we've made and the timeline for our future efforts moving into 2012 and beyond," he concluded.

Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin ® , an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin (TM) and Nyloxin (TM) Extra Strength, stronger versions of Cobroxin ® . These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.

The Shareholder Letter is available on the Company's website at: http://www.nutrapharma.com/4Q11_shareholder_letter.pdf

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin(TM) . For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

About Undiscovered Equities

Undiscovered Equities is a leading provider of equity research on high impact aggressive growth investment opportunities. Our services include research analysis on the energy and precious metals markets, news and financial data, market commentary and the Undiscovered Equities newsletter. Undiscovered Equities' staff of small cap investment professionals are dedicated to providing the investment community with the tools and avenues necessary to, invest their money wisely and build wealth. To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.